Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe asthma.

In parallel, Boston-based Kinaset Therapeutics Inc. in-licensed KN-002 (formerly VR588), an inhaled pan-JAK inhibitor from respiratory company Vectura Group plc (LSE:VEC) that is expected to enter the clinic in 1H21 to treat severe asthma. ...